TY - JOUR

T1 - In Vitro and In Vivo Evaluation of Fluorescently Labeled Borocaptate-Containing Liposomes

AU - Kanygin, Vladimir

AU - Zaboronok, Alexander

AU - Taskaeva, Iuliia

AU - Zavjalov, Evgenii

AU - Mukhamadiyarov, Rinat

AU - Kichigin, Aleksandr

AU - Kasatova, Anna

AU - Razumov, Ivan

AU - Sibirtsev, Roman

AU - Mathis, Bryan J.

N1 - Publisher Copyright: © 2020, Springer Science+Business Media, LLC, part of Springer Nature. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/1

Y1 - 2021/1

N2 - Boron neutron capture therapy (BNCT), a binary cancer therapeutic modality, has moved to a new phase since development of accelerator-based neutron sources and establishment of BNCT centers in Finland and Japan. That stimulated efforts for better boron delivery agent development. As liposomes have shown effective boron delivery properties and sufficient tumor retention, fluorescent liposome labelling may serve as a rapid method to study initial ability of newly synthesized liposomes to be captured by tumor cells prior to experiments on boron accumulation and neutron irradiation. In this work, we studied the accumulation and biodistribution of pegylated liposomes with encapsulated borocaptate (BSH) and a fluorescent label (Nile Red) in U87 (human glioblastoma), SW-620 (human colon carcinoma), SK-MEL-28 (human melanoma), FetMSC (mesenchymal human embryo stem cells), and EMBR (primary embryocytes) cell lines as well as an orthotopic xenograft model of U87 glioma in SCID mice. Results indicate that fluorescent microscopy is effective at determining the intracellular localization of the liposomes using a fluorescent label. The synthesized, pegylated liposomes showed higher accumulation in tumors compared to normal cells, with characteristic concentration peaks in SW-620 and U87 cell lines, and provided in vivo tumor selectivity with several-fold higher tumor tissue fluorescence at the 6-h timepoint.

AB - Boron neutron capture therapy (BNCT), a binary cancer therapeutic modality, has moved to a new phase since development of accelerator-based neutron sources and establishment of BNCT centers in Finland and Japan. That stimulated efforts for better boron delivery agent development. As liposomes have shown effective boron delivery properties and sufficient tumor retention, fluorescent liposome labelling may serve as a rapid method to study initial ability of newly synthesized liposomes to be captured by tumor cells prior to experiments on boron accumulation and neutron irradiation. In this work, we studied the accumulation and biodistribution of pegylated liposomes with encapsulated borocaptate (BSH) and a fluorescent label (Nile Red) in U87 (human glioblastoma), SW-620 (human colon carcinoma), SK-MEL-28 (human melanoma), FetMSC (mesenchymal human embryo stem cells), and EMBR (primary embryocytes) cell lines as well as an orthotopic xenograft model of U87 glioma in SCID mice. Results indicate that fluorescent microscopy is effective at determining the intracellular localization of the liposomes using a fluorescent label. The synthesized, pegylated liposomes showed higher accumulation in tumors compared to normal cells, with characteristic concentration peaks in SW-620 and U87 cell lines, and provided in vivo tumor selectivity with several-fold higher tumor tissue fluorescence at the 6-h timepoint.

KW - BNCT

KW - Borocaptate

KW - Drug delivery

KW - Fluorescence

KW - Liposomes

KW - TRANSFERRIN-PEG LIPOSOMES

KW - EFFICACY

KW - ORAL-CANCER

KW - MODEL

KW - DELIVERY VEHICLES

KW - GLIOBLASTOMA

KW - BORON-RICH LIPOSOMES

KW - NEUTRON-CAPTURE THERAPY

KW - MURINE TUMORS

KW - BRAIN

UR - http://www.scopus.com/inward/record.url?scp=85092765042&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/98a73036-e9a4-3029-86af-82e57a869cfb/

U2 - 10.1007/s10895-020-02637-5

DO - 10.1007/s10895-020-02637-5

M3 - Article

C2 - 33078252

AN - SCOPUS:85092765042

VL - 31

SP - 73

EP - 83

JO - Journal of Fluorescence

JF - Journal of Fluorescence

SN - 1053-0509

IS - 1

ER -